These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25695670)

  • 21. Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.
    Dineen TA; Weiss MM; Williamson T; Acton P; Babu-Khan S; Bartberger MD; Brown J; Chen K; Cheng Y; Citron M; Croghan MD; Dunn RT; Esmay J; Graceffa RF; Harried SS; Hickman D; Hitchcock SA; Horne DB; Huang H; Imbeah-Ampiah R; Judd T; Kaller MR; Kreiman CR; La DS; Li V; Lopez P; Louie S; Monenschein H; Nguyen TT; Pennington LD; San Miguel T; Sickmier EA; Vargas HM; Wahl RC; Wen PH; Whittington DA; Wood S; Xue Q; Yang BH; Patel VF; Zhong W
    J Med Chem; 2012 Nov; 55(21):9025-44. PubMed ID: 22468684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
    Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
    J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
    Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
    J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potency prediction of β-secretase (BACE-1) inhibitors using density functional methods.
    Roos K; Viklund J; Meuller J; Kaspersson K; Svensson M
    J Chem Inf Model; 2014 Mar; 54(3):818-25. PubMed ID: 24456077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carbazole-containing arylcarboxamides as BACE1 inhibitors.
    Bertini S; Asso V; Ghilardi E; Granchi C; Manera C; Minutolo F; Saccomanni G; Bortolato A; Mason J; Moro S; Macchia M
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6657-61. PubMed ID: 21986588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides.
    Rueeger H; Lueoend R; Rogel O; Rondeau JM; Möbitz H; Machauer R; Jacobson L; Staufenbiel M; Desrayaud S; Neumann U
    J Med Chem; 2012 Apr; 55(7):3364-86. PubMed ID: 22380629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, in vitro biological evaluation and molecular docking studies of benzimidamides as potential BACE1 inhibitors.
    Niu Y; Gao H; Xu F; Wang C; Liu P; Yang G; Sun Q; Xu P
    Chem Biol Drug Des; 2012 Nov; 80(5):775-80. PubMed ID: 22882897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011).
    Probst G; Xu YZ
    Expert Opin Ther Pat; 2012 May; 22(5):511-40. PubMed ID: 22512789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1).
    Cheng Y; Judd TC; Bartberger MD; Brown J; Chen K; Fremeau RT; Hickman D; Hitchcock SA; Jordan B; Li V; Lopez P; Louie SW; Luo Y; Michelsen K; Nixey T; Powers TS; Rattan C; Sickmier EA; St Jean DJ; Wahl RC; Wen PH; Wood S
    J Med Chem; 2011 Aug; 54(16):5836-57. PubMed ID: 21707077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.
    Hilpert H; Guba W; Woltering TJ; Wostl W; Pinard E; Mauser H; Mayweg AV; Rogers-Evans M; Humm R; Krummenacher D; Muser T; Schnider C; Jacobsen H; Ozmen L; Bergadano A; Banner DW; Hochstrasser R; Kuglstatter A; David-Pierson P; Fischer H; Polara A; Narquizian R
    J Med Chem; 2013 May; 56(10):3980-95. PubMed ID: 23590342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine β-Site APP Cleaving Enzyme-1 (BACE1) Inhibitors.
    Wu YJ; Guernon J; Shi J; Marcin L; Higgins M; Rajamani R; Muckelbauer J; Lewis H; Chang C; Camac D; Toyn JH; Ahlijanian MK; Albright CF; Macor JE; Thompson LA
    J Med Chem; 2016 Sep; 59(18):8593-600. PubMed ID: 27559936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of glutaminyl cyclase ameliorates amyloid pathology in an animal model of Alzheimer's disease via the modulation of γ-secretase activity.
    Song H; Chang YJ; Moon M; Park SK; Tran PT; Hoang VH; Lee J; Mook-Jung I
    J Alzheimers Dis; 2015; 43(3):797-807. PubMed ID: 25114069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [BACE1 inhibitors for the treatment of Alzheimer disease].
    Tomita T
    Nihon Rinsho; 2016 Mar; 74(3):427-31. PubMed ID: 27025081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spirocyclic β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid β in a higher species.
    Hunt KW; Cook AW; Watts RJ; Clark CT; Vigers G; Smith D; Metcalf AT; Gunawardana IW; Burkard M; Cox AA; Geck Do MK; Dutcher D; Thomas AA; Rana S; Kallan NC; DeLisle RK; Rizzi JP; Regal K; Sammond D; Groneberg R; Siu M; Purkey H; Lyssikatos JP; Marlow A; Liu X; Tang TP
    J Med Chem; 2013 Apr; 56(8):3379-403. PubMed ID: 23537249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2,2,2-Trifluoroethyl-thiadiazines: a patent evaluation of WO2016023927.
    Dotsenko VV; Chigorina EA; Krivokolysko SG
    Expert Opin Ther Pat; 2016 Dec; 26(12):1371-1376. PubMed ID: 27785946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease.
    Jeppsson F; Eketjäll S; Janson J; Karlström S; Gustavsson S; Olsson LL; Radesäter AC; Ploeger B; Cebers G; Kolmodin K; Swahn BM; von Berg S; Bueters T; Fälting J
    J Biol Chem; 2012 Nov; 287(49):41245-57. PubMed ID: 23048024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of BACE1 for therapeutic use in Alzheimer's disease.
    Luo X; Yan R
    Int J Clin Exp Pathol; 2010 Jul; 3(6):618-28. PubMed ID: 20661410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure- and property-based design of aminooxazoline xanthenes as selective, orally efficacious, and CNS penetrable BACE inhibitors for the treatment of Alzheimer's disease.
    Huang H; La DS; Cheng AC; Whittington DA; Patel VF; Chen K; Dineen TA; Epstein O; Graceffa R; Hickman D; Kiang YH; Louie S; Luo Y; Wahl RC; Wen PH; Wood S; Fremeau RT
    J Med Chem; 2012 Nov; 55(21):9156-69. PubMed ID: 22928914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A stereoselective approach to peptidomimetic BACE1 inhibitors.
    Butini S; Gabellieri E; Brindisi M; Giovani S; Maramai S; Kshirsagar G; Guarino E; Brogi S; La Pietra V; Giustiniano M; Marinelli L; Novellino E; Campiani G; Cappelli A; Gemma S
    Eur J Med Chem; 2013; 70():233-47. PubMed ID: 24158015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel pyrrolyl 2-aminopyridines as potent and selective human beta-secretase (BACE1) inhibitors.
    Malamas MS; Barnes K; Hui Y; Johnson M; Lovering F; Condon J; Fobare W; Solvibile W; Turner J; Hu Y; Manas ES; Fan K; Olland A; Chopra R; Bard J; Pangalos MN; Reinhart P; Robichaud AJ
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2068-73. PubMed ID: 20223661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.